

DAFTAR PUSTAKA

- Afera, S. L., Santosos, S. D., & Santosa, R. I. 2021. Rasio Albumin Kreatinin Urin Sebagai Deteksi Dini Gangguan Fungsi Ginjal pada Diabetes Melitus. *Jurnal SainHealth*, 5(2).
- American Diabetes Association (ADA). 2014. Diabetes Statistic. Diakses di <http://www.diabetes.org>
- Antari, Ni Kadek N & Esmon, Hindrata A. Pengalaman Belajar Lapangan : Diabetes Melitus Tipe 2. Fakultas Kedokteran Universitas Udayana. 2017.
- Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. *Clin Exp Nephrol* 2003; 7: 255–259.
- Bennett, P. Epidemiology of Type 2 Diabetes Mellitus. In Le Roithet.al, Diabetes Millitus a Fundamental and Clinical Text. Philadelphia: Lippincott William & Wilkin s.2008;43(1): 544-7.
- B. Guleng, Y. M. Lian, and J. L. Ren, "Mindin is upregulated during colitis and may activate NF- κ B in a TLR-9 mediated manner," *World Journal of Gastroenterology*, vol.16,no.9,pp. 1070–1075, 2010.
- Buraerah, Hakim. Analisis Faktor Risiko Diabetes tipe 2 di Puskesmas Tanrutedong, Sidenreng Rappang. *Jurnal Ilmiah Nasional*; 2010 [cited 2010 feb 17]. Available from :<http://lib.atmajaya.ac.id/default.aspx?tabID=61&src=a&id=186192>
- Chang Yp, Sun B, Han Z, Han F, Hu Si, Li Xy, Xue M, Yang Y, Chen L, Li Cj, Chen Lm. Saxagliptin Melemahkan Albuminuria Dengan Menghambat Transisi Epitel-Mesenkim Podosit Melalui Sdf-1 α Pada Nefropati Diabetik. *Frontiers in Pharmacology*. 2017: jilid 8, pasar 780. Doi: 10.3389/fphar.2017.00780.
- C. J. Raats, J. van den Born, M. A. Bakker et al., "Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies," *American Journal of Pathology*, vol. 156, no. 5, pp. 1749–1765, 2000.

Dai H., Liu Q., Liu B., Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy. *J. Diabetes Res.*, 2017 : 2615286.

Departemen Kesehatan. Pharmaceutical Care untuk Penyakit Diabetes Melitus. 2005.

Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 35, 2011. pp. S64-S71.

Dogan T, Yetim M, Celik O, Kalcik M, Ozcan O, Dogan I, Erenler AK, Bekar L, Karavelioglu Y. Investigation of mindin levels in hypertensive patients with left ventricular hypertrophy and QRS fragmentation on electrocardiography. *Acta Cardiol*. 2018 Dec; 73 (6):544-549.

Fatimah, Restyana Noor. 2015. Diabetes Melitus Tipe 2. *J Majority*. Volume 4. Nomor 5, Februari 2015.

Feinstein Y, Borrell V, Garcia C et al. F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. *Development* 1999; 126: 3637–3648.

Fishea T., Urinary biomarkers for early diabetic nephropathy in type 2 diabrtic patients. *Biomark. Res.*, 2015. 3:16.

Gluhovschi C., Gluhvschi G., Petrica L., Timar R., Velciov S., Ionita I. et al. Urinary Biomarkers in the assesment of Early Diabetic Nephropathy. *J. Diabetes. Res.* 2016:4626125.

Higashijima S, Nose A, Eguchi G et al. Mindin/F-spondin family: novel ECM proteins expressed in the zebrafish embryonic axis. *Dev Biol* 1997; 192: 211–227.

H. M. Regele, E. Fillipovic, B. Langer et al., “Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis,” *Journal of the American Society of Nephrology*, vol. 11, no. 3, pp. 403–412, 2000.

Inai, Y & Ihara Yoshito. Role of C-mannosylation in the secretion of mindin. Volume 1864, Issue, August 2020, 129632.

W. Jia, H. Li, and Y. W. He. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. *Blood* 2005; 106: 3854–3859.

Kahvecioglu S, Guclu M, Ustundag Y, Gul CB, Dogan I, Dagel T, Esen B, Akturk Esen S, Celik H, Esen I. Evaluation of serum Spondin 2 levels in the different stages of Type 2 diabetic nephropathy. *Nephrology (Carlton)*. 2015 Oct;20(10):721-726. doi: 10.1111/nep.12507.

K. Asanuma and P. Mundel, "The role of podocytes in glomerular pathobiology," *Clinical and Experimental Nephrology*, vol. 7, no. 4, pp. 255–259, 2003

Kerner, W., Bruckel, J. (2014). Definition, Classification and Diagnosis of Diabetes Mellitus. *Experimental and Clinical Endocrinology Diabetes*, 122(7): 384-386.

Liapis H., Romagnani P., Andres HJ., New Insight Into te Pathology of Podocyte Loss: Mitotiv catastrophe., *Am. J. Pathol.* 2013, 183 (5): 1364-1374.

Li, Yili & Cao, Chunzhang & Jia, Wei & Yu, Lily & Mo, Min & Wang, Qian & Huang, Yuping & Lim, Jae-Min & Ishihara, Mayumi & Wells, Lance & Azadi, Parastoo & Robinson, Howard & He, You-Wen & Zhang, Li & Mariuzza, Roy. (2009). Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule. *The EMBO journal*. 28. 286-97. 10.1038/emboj.2008.288.

Martins ALMdS, Bernardes AB, Ferreira VA, Wanderley DC, Araújo SDA, do Carmo Neto JR, dkk. (2023) Penilaian in situ Mindin sebagai biomarker lesi podosit pada nefropati diabetik. *PLoS ONE* 18 (5): e0284789. doi: 10.1371/journal.pone.0284789

Murakoshi, M., Tanimoto, M., Gohda, T., Hagiwara, S., Takagi, M., Horikoshi, S., Tomino, Y. Mindin : Penanda Baru Untuk Cedera Podosit Pada Nefropati Diabetik. *Nephrol Dial Transplant*. 2010; 26: 2153-2160. doi: 10.1093/ndt/gfq708.

Murakoshi, M., Gohda T., Tanimoto, M., Funabiki, K., Horikoshi, S., Tomino, Y. Review Artikel: Peran Mindin Dalam Nefropati Diabetik.

Hindawi Publishing Corporation Experimental Diabetes Researchl. 2011; 6. Doi: 10.1155/2011/486305.

- Nasution, Lisna K. 2017. Faktor-Faktor yang Memengaruhi Kejadian Diabetes Melitus Tipe 2 pada Wanita Usia Subur di Wilayah Kerja Puskesmas Pintu Padang Kabupaten Tapanuli Selatan. Tesis. Universitas Sumatera Utara. Medan.
- N. Ismail, B. Becker, P. Strzelczyk, and E. Ritz, "Renal disease and hypertension in non-insulin-dependent diabetes mellitus," *Kidney International*, vol. 55, no. 1, pp. 1–28, 1999.
- Prayuda, M. R. 2016. Hubungan Kadar Kreatinin Serum dengan Mikroalbuminuria pada Penderita Diabetes Melitus Tipe 2 di RSUD H. Abdul Moeloek Bandar Lampung. Universitas Lampung.
- Riskesdas. 2017. Badan Penelitian dan Pengembangan Kesehatan Dasar. Departemen Kesehatan Republik Indonesia.
- Ritz, E., Rychlik, I., Locatelli, F., and Halimi, S. (1999). End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. *Am. J. Kidney Dis.* 34, 795–808. doi: 10.1016/S0272-6386(99)70035-1.
- Rivandi, J. & Yonata, A. 2015. Hubungan Diabetes Melitus dengan Kejadian Gagal Ginjal Kronik. *Majority*. 4(9).
- S. Adler, "Characterization of glomerular epithelial cell matrix receptors," *American Journal of Pathology*, vol. 141, no. 3, pp. 571–578, 1992.
- S. Decramer, A. G. de Peredo, B. Breuil et al., "Urine in clinical proteomics," *Molecular and Cellular Proteomics*, vol. 7, no. 10, pp. 1850–1862, 2008.
- Sekulic, Miroslav & Sekulic, Simona Pichler. 2013. A Compendium of Urinary Biomarkers Indicative of Glomerular Podocytopathy. *Hindawi Publishing Corporation Pathology Research International*. Article ID 782395, 18 pages <http://dx.doi.org/10.1155/2013/782395>
- Soegondo S, Pranda S, Imam S. 2013. Penatalaksanaan Diabetes Melitus Terpadu. Jakarta: FKUI.

- Soewondo, P. 2007. Penyakit Metabolik Endokrin. Jakarta.
- Sujaya, I Nyoman. Pola Konsumsi Makanan Tradisional Bali sebagai Faktor Risiko Diabetes Melitus Tipe 2 di Tabanan. Jurnal Skala Husada. 2009;6(1):75-81.
- Slamet S. Diet pada diabetes Dalam Noer dkk. Buku ajar ilmu penyakit dalam. Edisi III.Jakarta: Balai Penerbit FK-ill;2008.
- Swastika, M. Rianasari Dwi. Evaluasi Pengobatan pada Kasus Diabetes Melitus dengan Komplikasi Nefropati Diabetik di Instalasi Rawat Inap Rumah Sakit Bethesda Yogyakarta Periode Tahun 2005. Skripsi. Universitas Sanata Dharma. 2007.
- Tanaka, Yuki & Kume, Shinji & Kitada, Munehiro & Kanasaki, Keizo & Uzu, Takashi & Maegawa, Hiroshi & Koya, Daisuke. (2012). Autophagy as a Therapeutic Target in Diabetic Nephropathy. Experimental diabetes research. 2012. 628978. 10.1155/2012/628978.
- Wang LF, Liu YS, Yang B, et al. The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation. Oncogene. 2018. 37,601-615.
- Wang, Qiang. Detection of serum Cys C and Hcy as well as urine mindin and NAG contents in patients with diabetic nephropathy and the value for early diagnosis of diseases. *Journal of Hainan Medical University*. 2016; 22(10): 48-51.
- Weil EJ., Lemley KV., Mason CC., Yee B., Jones LI., Blouch K., et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy, Kidney. Int. 2012, 82(9):1010-1017.
- W. Jia, H. Li, and Y. W. He, "The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment," Blood, vol. 106, no. 12, pp. 3854–3859, 2005.
- W. Jia, H. Li, and Y. W. He, "Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses," Journal of Immunology, vol. 180, no. 9, pp. 6255–6261, 2008.
- World Health Organization. 2015. Global Status Report On Non Communicable Disease 2014.

- Y. Li, C. Cao, W. Jia et al., “Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule,” *EMBO Journal*, vol. 28, no. 3, pp. 286–297, 2009.
- Y. W. He, H. Li, J. Zhang et al., “The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens,” *Nature Immunology*, vol. 5, no. 1, pp. 88–97, 2004.
- Zhang, L., Long, J., Jiang, W., Shi, Y., He, X., Zhou, Z., et al. (2016). Trends in chronic kidney disease in China. *N. Engl. J. Med.* 375, 905–906. doi: 10.1056/NEJMc1602469
- Z. Li, S. Garantziotis, W. Jia et al., “The extracellular matrix protein mindin regulates trafficking of murine eosinophils into the airspace,” *Journal of Leukocyte Biology*, vol. 85, no. 1, pp. 124–131, 2009.

LAMPIRAN

Curiculum Vitae (CV)

Data Pribadi

Nama Lengkap : Regina Andini Maulidya
TTL : Ujung Pandang, 28 Juli 1996
Jenis Kelamin : Perempuan
Agama : Islam
E-mail : reginaandinim@gmail.com
Alamat : Perum. Villa Megasari, Kel. Gunung Sari,
Kec. Rappocini, Kota Makassar, Prov. SulSel

Data Pendidikan

SD : SDN Center Pattallassang
SMP : SMPN 2 Takalar
SMA : SMAN 1 Takalar
Perguruan Tinggi : D-IV Poltekkes Kemenkes Makassar

Master Tabel Penelitian

NO	KODE SPESIMEN	JENIS KELAMIN	UMUR (Tahun)	RIWAYAT DM	Mindin /Spondin	ACR	HbA1c
1	2	P	66	DMT2	60,16	13	13,2
2	8	L	53	DMT2	17,46	41	10,8
3	14	P	55	DMT2	53,78	75	10,3
4	19	L	60	DMT2	185,36	721	7,6
5	22	P	61	DMT2	364,85	59	8,3
6	26	L	69	DMT2	42,65	12	8
7	27	P	56	DMT2	37,41	19	8,1
8	28	P	55	DMT2	205,59	4	10
9	31	P	79	DMT2	281,35	7	5,3
10	36	L	52	DMT2	257,89	7	12,6
11	37	L	37	DMT2	240,05	4	10,4
12	40	P	49	DMT2	71,57	47	7,9
13	41	P	47	DMT2	116,81	128	7,6
14	42	P	63	DMT2	105,38	7	10
15	43	P	58	DMT2	485,38	6	10,1
16	44	P	59	DMT2	272,79	130	7,4
17	45	L	65	DMT2	50,77	15	7,7
18	46	P	43	DMT2	712,87	1285	11,5
19	48	L	63	DMT2	496,02	135	15,9
20	49	L	62	DMT2	38,85	2	9,9
21	50	P	56	DMT2	26,37	8023	6,3
22	52	P	52	DMT2	57,55	4	5,8
23	53	L	51	DMT2	106,2	2010	8,3
24	54	L	44	DMT2	64,16	6	6,6
25	56	P	61	DMT2	18,38	155	14,4
26	57	P	56	DMT2	23,42	12	7,1
27	58	L	70	DMT2	54,11	156	7,7
28	60	L	64	DMT2	111,32	27	6,3
29	62	L	54	DMT2	28,61	21	9

30	72	P	45	DMT2	1897	7	8,1
31	75	P	57	DMT2	140,69	7	5,8
32	80	P	53	DMT2	67,73	13	8,8
33	82	L	67	DMT2	221,95	23	9,7
34	83	P	63	DMT2	69,07	3	6,2
35	84	L	61	DMT2	118,1	33	10,1
36	85	L	62	DMT2	25,82	63	6,6
37	86	L	47	DMT2	40,65	260	9,7
38	89	L	84	DMT2	72,56	901	9,2
39	90	P	65	DMT2	55,02	22	13,8
40	91	P	67	DMT2	55,46	8	6,9
41	92	L	61	DMT2	817,52	7	6,7
42	93	P	72	DMT2	62,25	9	6
43	94	L	57	DMT2	312,62	27	7,1
44	95	P	63	DMT2	20,64	65	9,4
45	96	L	53	DMT2	541,6	22	7,2
46	97	P	58	DMT2	17,67	11	7,2
47	98	L	52	DMT2	89,66	2	5,9
48	99	L	39	DMT2	34,22	2	8,5
49	101	P	63	DMT2	476,46	376	12,4
50	102	P	28	DMT2	539,77	3	11,4
51	105	P	58	DMT2	26,95	26	13,9
52	107	L	51	NON	106,93		
53	108	L	43	NON	52,07		
54	109	L	33	NON	12,29		
55	110	L	36	NON	36,5		
56	111	L	40	NON	267,77		
57	112	L	41	NON	40,63		
58	9	P	37	NON	34,49		
59	10	P	31	NON	90,98		
60	11	L	43	NON	26,59		
61	12	P	35	NON	20,45		
62	13	L	37	NON	51,6		
63	63	L	34	NON	53,33		

64	64	L	38	NON	116,4		
65	68	L	34	NON	9,76		
66	15	L	39	NON	731,31		
67	16	P	35	NON	4,08		
68	17	P	40	NON	525,46		
69	18	P	34	NON	51,14		
70	51	P	34	NON	1804,31		
71	55	P	33	NON	287,25		
72	59	L	33	NON	245,23		
73	100	P	50	NON	14,62		
74	38	P	36	NON	126,2		
75	29	L	35	NON	41,29		
76	20	L	38	NON	16,94		

Jenis Kelamin_DMT2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Perempuan	28	54.9	54.9	54.9
	Laki-laki	23	45.1	45.1	100.0
	Total	51	100.0	100.0	

Usia_DMT2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	28-40 tahun	3	5.9	5.9	5.9
	41-50 tahun	6	11.8	11.8	17.6
	51-60 tahun	20	39.2	39.2	56.9
	61-70 tahun	19	37.3	37.3	94.1
	> 70 tahun	3	5.9	5.9	100.0
	Total	51	100.0	100.0	

ALB_DMT2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 30 mg/g	32	62.7	62.7	62.7
	> 30 mg/g	19	37.3	37.3	100.0
	Total	51	100.0	100.0	

HbA1c_DMT2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 7	12	23.5	23.5	23.5
	> 7	39	76.5	76.5	100.0
	Total	51	100.0	100.0	

Statistics

		Jenis	
		Kelamin_Non	
N	DM	Usia_Non DM	
Valid	25	25	
Missing	0	0	

Jenis Kelamin_Non DM

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Perempuan	10	40.0	40.0	40.0
	Laki-laki	15	60.0	60.0	100.0
	Total	25	100.0	100.0	

Usia_Non DM

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	28-40 tahun	20	80.0	80.0	80.0
	41-50 tahun	4	16.0	16.0	96.0
	51-60 tahun	1	4.0	4.0	100.0
	Total	25	100.0	100.0	

Case Processing Summary

Mindin	DMT2	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Mindin	DMT2	51	100.0%	0	0.0%	51	100.0%
	Non DM	25	100.0%	0	0.0%	25	100.0%

Descriptives

	Mindin	Statistic	Std. Error
Mindin	DMT2	Mean	201.7749
		95% Confidence Interval for Lower Bound	114.8287
		Mean	288.7211
		5% Trimmed Mean	155.5269
		Median	71.5700
		Variance	95565.664
		Std. Deviation	309.13697
		Minimum	17.46
		Maximum	1897.00
		Range	1879.54
		Interquartile Range	217.24
		Skewness	3.718 .333
		Kurtosis	17.889 .656
Non DM	Mean	190.7048	75.71203
		95% Confidence Interval for Lower Bound	34.4429
		Mean	346.9667
		5% Trimmed Mean	123.2872
		Median	51.6000
		Variance	143307.773
		Std. Deviation	378.56013
		Minimum	4.08
		Maximum	1804.31
		Range	1800.23
		Interquartile Range	162.20
		Skewness	3.617 .464
		Kurtosis	14.537 .902

Tests of Normality

	Mindin	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Mindin	DMT2	.276	51	.000	.584	51	.000
	Non DM	.328	25	.000	.507	25	.000

a. Lilliefors Significance Correction

Mann-Whitney Test

Ranks

	Mindin	N	Mean Rank	Sum of Ranks
Mindin	DMT2	51	41.20	2101.00
	Non DM	25	33.00	825.00
	Total	76		

Test Statistics^a

Mindin
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)

a. Grouping Variable: Mindin

Correlations

			ACR-DTM2	MINDIN_DMT2
Spearman's rho	ACR-DTM2	Correlation Coefficient	1.000	-.080
		Sig. (2-tailed)	.	.577
		N	51	51
	MINDIN_DMT2	Correlation Coefficient	-.080	1.000
		Sig. (2-tailed)	.577	.
		N	51	51



REKOMENDASI PERSETUJUAN ETIK

Nomor : 730/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 25 September 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23060432			No Sponsor	
Peneliti Utama	Regina Andini Maulidya, S.Tr.Kes			Sponsor	
Judul Peneliti	Analisis Kadar Mindin Urin pada Penderita Diabetes Melitus Tipe 2				
No Versi Protokol	2			Tanggal Versi	25 September 2023
No Versi PSP	2			Tanggal Versi	25 September 2023
Tempat Penelitian	RS Universitas Hasanuddin Makassar				
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku 25 September 2023 sampai 25 September 2024	Frekuensi review lanjutan	
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, Sp.MK, Subsp. Bakt(K)			Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, Sp.MK(K)			Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



